In a separate retrospective study of patients with PTCL, in which > 85% of patients with the most common subtypes received anthracycline-containing regimens, the median OS ranged from 1 to 5 years for subtypes other than ALK-positive ALCL (Vose et al., 2008). The gene discussed is ALK; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.